{
    "author": "Rob Stein",
    "date_published": "2026-09-29T17:00:08.000Z",
    "dek": null,
    "direction": "ltr",
    "domain": "www.npr.org",
    "excerpt": "Origin Genomics aims to prove that the potential benefits of its technology for editing disease-causing genes in human embryos outweigh the risks.",
    "lead_image_url": "https://npr.brightspotcdn.com/dims3/default/strip/false/crop/5182x2915+0+261/resize/1400/quality/85/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F56%2F87%2Fae45aab04fdf8d47954c20869c83%2Fcalle-20260914-00352.jpg",
    "next_page_url": null,
    "rendered_pages": 1,
    "title": "This startup wants to prove gene-editing embryos is safe for making healthy babies",
    "total_pages": 1,
    "url": "https://www.npr.org/2026/09/29/nx-s1-5950439/embryo-gene-editing-babies-biotech",
    "word_count": 1749
}